P < 0.0001). When individual variables were subjected to logistic regression, male sex, age, blood pressure, smoking status, and cholesterol concentrations were all significant predictors of heart disease but when corrected for the Framingham risk score no single factor remained predictive on its own.
Comment
These results confirm that the Framingham model reliably predicts the absolute risk of heart disease in white men and women in the United Kingdom when the annual risk is above 1.5% , but the model underestimates the risk when the absolute risk is lower. This is consistent with studies that have shown that the model is inaccurate when applied to low risk populations. 5 We might have achieved a closer fit with the model by measuring concentrations of high density lipoprotein cholesterol and using a 4 to 12 year follow up period similar to that from which the model was derived. Nevertheless, the recommended threshold for treatment with lipid lowering drugs is based on an annual risk of 3% per year, 1 so the Framingham model can be used in clinical practice in the UK population.
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Competing interests: None declared. S Ramachandran, J M French, M P J Vanderpump, P Croft, R H Neary Current guidelines for prescribing lipid lowering drugs are based on an individual's risk of coronary heart disease rather than on the reduction in risk that treatment may bring. We report a strategy for making treatment decisions that combines computer assisted calculation of absolute risk with an estimate of benefit to the patient from treatment.
Subjects, methods, and results
During a period of 14 months, 17 randomly selected general practices (63 practitioners) in north Staffordshire were asked to send to the department of clinical biochemistry their requests for coronary heart disease risk assessment on patients being considered for lipid lowering drug treatment. We used the Framingham statistical model to estimate a patient's absolute risk of coronary heart disease over five years. The reduction in risk that treatment would bring over the next five years was calculated from the product of the absolute five year risk and the risk reduction observed in clinical trials or meta-analysis. The reduction in risk associated with cholesterol lowering drugs was 0.31, 1 which was adjusted for the patient's age in line with a meta-analysis showing less benefit with increasing age. 2 The reduction in risk was calculated as the absolute five year risk×0.31×age factor (the age factor = 0.02357(a) 2 − 3.719(a) + 165.3, where (a) = the patient's age, calculated from 2 ). A database running on Microsoft Access (version 7 for Windows 95) was developed. This calculated absolute risk, risk reduction (and number needed to treat), and the mean five year risk in the local population for that age and sex.
Patients were grouped according to whether they would be recommended for treatment because (a) their absolute risk of coronary heart disease was greater than 15% in five years; (b) treatment would reduce their absolute risk of heart disease by more than 4.45% over five years (equivalent to the treatment benefit in the high risk group in the Scottish study 3 ); or (c) they met both criteria. The Mann-Whitney U test and the 2 test were used to compare the levels of risk factors in these groups.
We received assessment requests for 1320 patients. Patients with vascular disease, aged over 75 years, or already taking lipid lowering drugs were excluded (393 patients). The remaining 927 patients included 484 men (55%), 247 smokers (27%), and 139 with diabetes (15%). The figure shows the breakdown of risk factors in the groups of patients for whom treatment would be recommended.
Patients recommended for treatment because of absolute risk but not benefit (n = 34) were less likely to be hyperlipidaemic than those recommended because of benefit but not risk (n = 17). The former group had a lower concentration of total cholesterol (mean difference 0.97 mmol/l, P = 0.007); a higher concentration of high density lipoprotein cholesterol (0.14 mmol/l, P = 0.05); a lower ratio of total cholesterol to high density lipoprotein cholesterol (1.84, P = 0.0007); and a lower concentration of triglycerides (2.2 mmol/l, P = 0.04) than patients recommended for treatment on the basis of benefit. They were also older (mean difference 19.9 years, P < 0.0001) and tended to have a higher systolic blood pressure (13.9 mm Hg, P = 0.09), although fewer of them smoked (29.4% v 70.6%, P = 0.005).
Comment
Recommendations based on absolute risk may not achieve the most appropriate prescribing as lipid lowering drugs may be given to patients whose main coronary risk factor is not hyperlipidaemia. By ignoring risk reduction, doctors may miss an opportunity for coronary prevention in younger people whose absolute risk threshold in five years is below 15%. These patients stand to gain more through treatment of their main risk factor (hyperlipidaemia), particularly when this is viewed in the context of their greater life expectancy.
We calculate and report benefit from other measures too, using risk reductions of 16% for antihypertensive drugs, 4 since this article was accepted for publication, suggests no difference in relative risk reduction in subjects older or younger than 65 years. The conclusion from this analysis may not necessarily apply across the wider age range commonly encountered by those running primary prevention clinics; nevertheless, at this stage more data are required to establish whether the benefits of lipid lowering therapy are age related.
Contributors: RHN and SR set up the study, developed the database, and evaluated the data with PC. The report was written jointly by all authors. We thank Dr Giri Rajaratnam, Director of Heath Policy and Public Health Medicine for supporting this programme. Meningococcal infection can be life threatening. Most infections are sporadic, although clusters do occur, particularly in teenagers. The management of clusters includes giving antibiotics to a defined group. Vaccination has a role in clusters of meningococcal serogroup C infection. Although ciprofloxacin 500 mg orally is not licensed for prophylaxis against meningococcal disease, it is used because it reduces meningococcal carriage, 1 can be given as a single dose, and, unlike rifampicin, does not interact adversely with the contraceptive pill. 2 We report on anaphylactoid reactions to ciprofloxacin in three students and a close contact with meninogoccal infection (table) .
Two cases (one fatal) of meningococcal infection occurred in first year university students within 12 days of each other. Ciprofloxacin 500 mg orally was offered to all the 4253 students in their first year at the university; around 3200 accepted.
Three cases of anaphylactoid reaction occurred-a rate of about 1:1000, much higher than the 1:100 000 quoted (12 cases in a population of 972 000). 3 Two of the three students had no history of atopic illness. All three students and the contact recovered. Additional adverse reactions were mild skin rashes in three students and nausea and vomiting in two.
A high rate of serious adverse events must be balanced by clear benefits to the target group. Ciprofloxacin clears meningococcal carriage so reducing transmission to a susceptible host. As carriers do not become cases the benefits from ciprofloxacin are for the community not the individual. The risk of a second case of infection among close contacts is 500 to 1000 times higher than in the general population. 4 The risk of a third case in a student population that has already had two cases is unknown. 
Serious allergic reactions to ciprofloxacin

